Results 41 to 50 of about 39,275 (210)
Journal of Parkinson’s Disease, 2020 Background: Parkinson’s disease (PD) is a progressive neurodegenerative disease for which there is no cure. In a clinical trial, the glucagon-like peptide-1 (GLP-1) receptor agonist exendin-4 has shown good protective effects in PD patients.
Lingyu Zhang +6 more
doaj +1 more source
Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist
Health Sciences Review, 2022 Glucagon-like peptide 1 (GLP-1) receptor agonists have acquired importance in Type 2 diabetes (T2D) treatment due to their glycemic advantages, cardiorenal effects, and favorable body weight. Despite this, the continuous discovery of higher effectiveness
Rouchan Ali +2 more
doaj +1 more source
The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs [PDF]
, 2013 G protein coupled receptors (GPCRs) are the most historically successful therapeutic targets. Despite this success there are many important aspects of GPCR pharmacology and function that have yet to be exploited to their full therapeutic potential.
Hudson, Brian D. +2 more
core +1 more source
Molecular Metabolism, 2022 Objective: Obesity and its associated comorbidities represent a global health challenge with a need for well-tolerated, effective, and mechanistically diverse pharmaceutical interventions.
Tina Zimmermann +14 more
doaj +1 more source
In Vivo Imaging of Transplanted Islets with ^(64)Cu-DO3A-VS-Cys^(40)-Exendin-4 by Targeting GLP-1 Receptor [PDF]
, 2011 Glucagon-like peptide 1 receptor (GLP-1R) is highly expressed in pancreatic islets, especially on β-cells. Therefore, a properly labeled ligand that binds to GLP-1R could be used for in vivo pancreatic islet imaging.
Bading, James R. +11 more
core +2 more sources
Glucagon-like peptide analogues for type 2 diabetes mellitus : systematic review and meta-analysis [PDF]
, 2010 Background Glucagon-like peptide (GLP-1) analogues are a new class of drugs used in the treatment of type 2 diabetes. They are given by injection, and regulate glucose levels by stimulating glucose-dependent insulin secretion and biosynthesis ...
Clar, C. +4 more
core +5 more sources
In-Silico Design of Novel Glucagon-Like Peptide 1 Mutants as Candidate for New Peptide Agonist Drugs
Hayati Journal of Biosciences, 2021 The binding of glucagon-like peptide 1 (GLP-1) incretin hormone and its receptor GLP-1R plays an important role in the human body. The GLP-1 acts as the insulin secretion stimulator through a GLP-1R agonist activation to avoid the type 2 diabetes ...
Tony Sumaryada +4 more
doaj
Journal of Diabetes Investigation, 2022 Aims/Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) might be less effective in patients with severe hyperglycemia, because hyperglycemia downregulated the GLP‐1 receptor in an animal study.
Yumie Takeshita +8 more
doaj +1 more source
Value of the radiolabelled GLP-1 receptor antagonist exendin(9-39) for targeting of GLP-1 receptor-expressing pancreatic tissues in mice and humans [PDF]
, 2018 Purpose: Radiolabelled glucagon-like peptide 1 (GLP-1) receptor agonists have recently been shown to successfully image benign insulinomas in patients.
Reubi, Jean, Waser, Beatrice
core
Incretin-based therapy for the treatment of bone fragility in diabetes mellitus [PDF]
, 2018 Bone fractures are common comorbidities of type 2 diabetes mellitus (T2DM). Bone fracture incidence seems to develop due to increased risk of falls, poor bone quality and/or anti-diabetic medications.
B. Bouvard +3 more
core +3 more sources